The insulin like growth factor-II/mannose-6-phosphate (IGF-II/ M6P) receptor has been detected in many cells and tissues. In the rat, there is a dramatic developmental regulation of IGF-II/MGP receptor expression, the receptor being high in fetal and neonatal tissues and declining thereafter. We have systematically studied the expression of the human IGF-II/MGP receptor protein in tissues from 10 human fetuses and infants (age 23 weeks gestation to 24 months postnatal). We have asked 1) whether there is differential expression among different organs, and 2) whether or not the human IGF-II/MGP receptor is developmentally regulated from 23 weeks gestation to 24 months postnatal. Protein was extracted from human tissues using a buffer containing 2% sodium dodecyl sulfate and 2% Triton X-100. Aliquots of the protein extracts were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting using an anti-IGF-II/MGP receptor antiserum (no. 66416) and lz51-protein A or an immunoperoxidase stain. IGF-II/MGP receptor immunoreactivity was detected in all tissues studied with the highest amount of receptor being expressed in heart, thymus, and kidney and the lowest receptor content being measured in brain and muscle. The receptor content in ovary, testis, lung, and spleen was intermediate. The apparent molecular weight of the IGF-II/MGP receptor (220,000 kilos without reduction of disulfide bonds) varied among the different tissues: in brain the receptor was of lower molecular weight than in other organs. Immunoquantitation experiments employing Y-protein A and protein extracts from human kidney at different ages revealed a small, albeit not significant, difference of the receptor content between fetal and postnatal tissues: as in other species, larger amounts of receptor seemed to be present in fetal than in postnatal organs. In addition, no significant difference of the receptor content between human fetal liver and early postnatal liver was measured employing Y-protein A-immunoquantitation in three fetal and five postnatal liver tissue samples. The distribution of IGF-binding protein (IGEBP) species, another abundant and major class of IGF binding principles, was also measured in human fetal and early postnatal lung, liver, kidney, muscle, and brain using Western ligand blotting with '251-IGF-II: as with IGF-II/MGP receptor immunoreactivity there was differential expression of the different classes of IGFBPs in the various organs. In conclusion, 1) the IGF-II/MGP receptor is present in multipie human tissues, 2) the human IGF-II/MGP recentor is variablv exnressed in different organs, 3) there is a m&h lesser degree of developmental regulation of IGF-II/ M6P receptor expression in the human than has been reported for the rat or sheep, 4) the differential pattern of distribution of IGF-II/MGP receptor and IGFBPs in the various organs throughout fetal and early postnatal human life points to an important and tissue specific role of the IGF binding principles in development and growth. (J Clin Endocrinol Metab 75: 424-431,1992) 
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Results

Specificity of immunodetection of IGF-IIjM6P receptors in human tissues
When protein extracts from human lung tissues were immunoblotted using anti-IGF-II/M6P receptor antiserum 66416, a single band at approximately 220 kilos mol wt corresponding to the approximate molecular weight of the IGF-II/M6P receptor upon SDS-PAGE was detected on the nitrocellulose sheets and no other band was stained (Fig. 1) . When control serum from normal rabbit was used instead of the antiserum no protein band was detected (data not shown). The specific receptor band was found in all lung tissues examined irrespective of the age of the donor: it was In contrast, when protein extracts from human kidney were examined by immunoblotting, not only the 220-kilodalton (kDa) receptor band was stained but also protein bands at 140 and at 72, 77, and 82 kDa were detected ( Fig. 2A) : the latter species were also seen when human kidney proteins were analyzed using control rabbit serum instead of the antireceptor antiserum (Fig. 2B) . These proteins were also seen on blots when only the avidin horse radish peroxidase complex was added without prior exposure of the nitrocellulose sheets to any serum and/or biotinylated second antibody (data not shown). In addition, these bands had no peroxidase activity as shown by enzymatic testing using 4-chloro-a-naphtol as staining reagent and H202 as substrate (data not shown). These results suggest that the immunostaining procedure used in these experiments detects biotinylated proteins which are present in some (kidney, liver, muscle) but not in other (lung, brain) human organs. The anti-IGF-II/MbP receptor antiserum used throughout these experiments, however, is specific for the human IGF-II/M6P receptor as has been described originally (31). As in lung tissue, the IGF-II/MGP receptor band at an approximate molecular weight of 220 kilos was present in kidney tissues at all ages examined: it was seen in kidney extracts from 23,26, and 41 weeks gestation fetuses and also from infants of 3,4, 13, 18, and 24 month postnatal age ( Fig.  2A) .
Immunodetection of IGF-II/M6P receptor protein-variable expression of the receptor in multiple human tissues
When tissue extracts of heart, psoatic muscle, lung, kidney, liver, brain, testis, ovary, spleen, and thymus from 10 human fetuses and infants were analyzed for IGF-II/M6P receptor content, all organs examined contained detectable amounts of receptor protein (Fig. 3, A, B, C immunoblots showing the analysis of tissue extracts from one fetus (25 weeks gestation) or infant (3-and 13-month postnatal age) respectively, are shown (Fig. 3, A, B, C) . The apparent molecular weight of the receptor band varied among the organs studied: generally, the receptor in brain was of lower molecular weight than the IGF-II/M6P receptor species in the remaining eight tissues. In some organs (thymus, liver, lung, ovary, spleen) doublet bands were occasionally detected (Figs. 3 and 4) . The amount of immunoreactivity measured in the different organs varied considerably. However, when the organs were grouped according to their IGF-II/M6P receptor content as estimated from 10 immunoblots, heart, thymus, and kidney consistently contained the highest amount of IGF-II/M6P receptor immunoreactivity whereas brain and muscle expressed the lowest level of IGF-II/MBP receptor immunoreactivity. The receptor content in ovary, testis, liver, lung, and spleen was intermediate ( Table 1) .
Immunoquantitation of IGF-II/MBP receptor expression during human fetal life and early infancy
The putative developmental regulation of IGF-II/M6P receptor expression was studied by immunoblotting tissue extracts from the same organ of donors of different ages: when protein extracts of lung, liver, kidney, thymus, and heart from human fetuses (23,26,35, and 41 weeks gestation) and infants (3, 4, 13, 18, and 24 months of age) were subjected to SDS-PAGE and immunoblotted using the specific anti-IGF-II/M6P receptor antiserum 66416, the receptor protein was again found in all organs and at all ages examined: there was considerable variation of the amount of receptor protein as measured by immunoblotting between ages. However, there was no clear and consistent pattern of variation which would have indicated a developmental regulation of receptor expression in the human between 23 weeks of gestation and 24 months postnatal (Fig. 4) . In addition, no sex difference of receptor expression was apparent (data not shown). To quantitate the relative amount of IGF-II/M6P receptor protein in human kidney and liver at different age points further, immunoblotting was performed using lz51-protein A and autoradiography for visualization of receptor species. Specific receptor bands were then cut out from the nitrocellulose sheets and radioactivity counted in a y-counter. Again, there was considerable variation in receptor content of the same sample between experiments. More importantly, receptor content of different samples also varied greatly. In kidney, receptor content was apparently higher in samples that were obtained from fetuses than in postnatal samples. However, when statistical analysis of relative receptor content at different ages was performed, comparing three prenatal samples with four postnatal samples, no statistically significant difference was found (Table 2 ). In addition, no significant difference of IGF-II/M6P receptor content between three fetal and five postnatal liver samples was detected ( Table 2) . Immunoblotting was performed as described in Fig. 1 . A, 25 weeks gestation; B, 3 months postnatal; C, 13 months postnatal.
multiple IGFBP species in the same organs, protein extracts from five different human tissues (psoatic muscle, brain, liver, lung, and kidney) were analyzed by SDS-PAGE and ligand blotting using 1251-IGF-II. Five distinct radiolabeled protein species with an approximate molecular weight of 43, 38, 34, 30, and 20 kilos, respectively, were detected (Fig. 5) . The intensity of the radiolabeled bands varied among the tissues studied: in brain, the 34-kDa band was predominant, while in psoatic muscle, the 30-kDa species was the major band as seen in seven ligand blotting experiments using tissue samples from eight fetuses and infants. The apparent has also been found on many cells including cell lines from human origin (24,37) and in human brain, liver, and placenta (1, 2, 54) . In this study, we have measured the receptor in solubilized whole tissue extracts from human fetuses and infants ranging in age from 23 weeks gestation to 2 yr postnatal. IGF-II/M6P receptor immunoreactivity was present in all tissues examined (brain, kidney, liver, lung, heart, testis, ovary, thymus, and spleen). As in the rat (50), brain contained the lowest concentration of IGF-II/M6P receptor protein, and heart and kidney consistently contained large amounts of receptor immunoreactivity. In addition, thymus also contained higher amounts of the receptor. Muscle, which contained high amounts of receptor protein in the rat, had only low receptor content in the human. The receptor content in ovary, testis, lung, and spleen was intermediate. As reported for the rat (50, 55), the human IGF-II/M6P receptor varied in size. Consistent with the results in the rat, the receptor in brain was smaller in size than that in other tissues. Presumably, this variation in receptor size reflects differential glycosylation of the receptor in the different tissues as has been suggested in the literature (55). Such variation in size also occurs during receptor synthesis in cells in culture (56, 57). Immunoreactive receptor species of lower molecular weight could thus reflect receptor precursors and indicate tissues of high receptor turnover or receptor synthesis. Alternatively, lower molecular weight receptor species could represent degradation products in proteolytic tissues (37, 48).
As with the IGF-II/M6P receptor protein there was also differential expression of IGFBP species in different organs: brain predominantly contained a 34-kDa IGFBP consistent with reports in the literature of the expression of such a specific 34-kDa IGFBP in cerebrospinal fluid (52). The differential expression of IGF-II/M6P receptors and IGFBP species in different human tissues points to specific biological In the rat, a dramatic (up to loo-fold) difference in the amount of IGF-II/M6P receptor between fetal and postnatal serum (46) and tissues (50) has been reported. In sheep and monkey serum, developmental regulation of IGF-II/M6P receptor expression has also been suggested (47, 51). In the human, we have found only a minimal difference of receptor content between prenatal and postnatal kidney and no such difference in liver tissues (between 23 weeks gestation and 24 months postnatal age). It is possible that the failure to detect a significant developmental regulation of receptor expression in the human was due to 1) autolytic processes which might affect different tissues at different ages in a differential manner. However, no signs of degradation (protein smear, etc.) appeared on any of the immunoblots, and other nonreceptor related proteins (i.e. biotinylated enzymes) expressed a clear developmental pattern (Fig. 2) . 2) Alternatively, a more pronounced developmental regulation of IGF-II/M6P receptor expression might occur much earlier (before 23 weeks of gestation) in human life than in embryologically comparable stages of development in the rat. It is interesting to note that whereas in the rat not only the IGF-II/M6P receptor but also the ligand, i.e. IGF-II itself, are developmentally regulated, in the human both the amount of IGF-II (l-3) and of the IGF-II/M6P receptor (this study) are barely or only to a small extent regulated during fetal and early postnatal development. 3) Failure to detect a significant difference of receptor content between fetal and postnatal tissues might also be due to the large variation caused by the detection technique (immunoblots) ( Table 2 ). However, when the receptor content of different organs was compared, a clear grouping of tissues with organs of high, intermediate, and low receptor content was evident. If a developmental pattern (fetal VS. postnatal) was as pronounced in the human as in other species (rat, sheep) (lOO-fold difference!), the relatively large variability of the technique and potential intersample variations would still not mask such a large difference.
Since the IGF-II/M6P receptor is present in all tissues examined and at all ages tested we hypothesize that this receptor type is involved in general functions of development and metabolism. The variable amounts of receptor protein present in different organs at different times of development make the IGF-II/M6P receptor a likely candidate of regulatory processes that might be involved in organ development, growth, and tissue remodeling. The receptor would add to the variability of IGF binding capacity in different tissues caused by the differential expression of IGFBP classes in the various organs. In addition, the IGF-II/M6P receptor binds two classes of ligands, namely, a growth factor, IGF-II, and a number of lysosomal enzymes bearing the mannose-6-phosphate recognition marker (29, 30). This latter function might also be of biological importance during development and in different tissues. The fact that the IGF-II/M6P receptor maintains-as demonstrated by receptor-ligand blotting (data not shown)-its function of binding IGF-II in all tissues examined, further points to an interconnected network of tissue degradation and growth processes that meet at the cellular level, i.e. at a common receptor site.
